Document is current
Any future updates will be listed below
-
Authors
Nam, Yoonhee https://orcid.org/0009-0008-2120-1107
Gomez, Karen
Reynier, Jean-Baptiste https://orcid.org/0000-0001-8914-0461
Khamnei, Cole
Aitken, Michael
Zheng, Vivian https://orcid.org/0009-0009-9628-8945
Lhakhang, Tenzin
Casula, Milena https://orcid.org/0000-0002-5079-9864
Palmieri, Giuseppe https://orcid.org/0000-0002-4350-2276
Cossu, Antonio
Levine, Arnold https://orcid.org/0000-0002-1871-6387
Tiacci, Enrico
Rabadan, Raul https://orcid.org/0000-0001-7946-9255
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253126, U01CA243073)
Fondazione AIRC
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 5 June 2025
First Online: 1 July 2025
Competing interests
: R. Rabadan is the founder of Genotwin, a member of the advisory board of Diatech Pharmacogenetics and Flahy. None of these activities are related to the results in the current manuscript. The remaining authors declare no competing interests.
